Skip to main content
. 2017 Feb 13;11(2):189–195. doi: 10.5009/gnl15562

Fig. 3.

Fig. 3

Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and emtricitabine combination therapy in lamivudine-resistant patients with chronic hepatitis B in a randomized double-blind controlled trial. Intention-to-treat population shown. Adapted from Fung S, et al. Gastroenterology 2014;146:980–988.e1, with permission from El-sevier.29

FTC, emtricitabine.